Clareo Health | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Part A: Patient must have histologically or cytologically confirmed advanced and/or metastatic solid tumor malignancies for which standard curative or palliative measures do not exist, are no longer effective, or are not acceptable to the patient
Eastern Cooperative Oncology Group Performance Status 0-1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Fresh biopsies may be required
Negative HIV, hepatitis B, or hepatitis C test result
Women of childbearing potential and male participants must agree to remain abstinent or use contraceptive methods as defined by the protocol
Histologically confirmed, unresectable stage III or stage IV melanoma
Previously treated with approved anti-programmed death-ligand 1 (PD-L1)/anti-programmed death-1 (PD-1) agents with or without approved anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) therapy and up to one additional treatment regimen
Histologically confirmed advanced NSCLC
Previously treated with approved PD-L1/PD-1 inhibitors and platinum-based chemotherapy
Not more than 2 prior lines of treatment for metastatic disease are allowed prior to enrolling to the study
Participants must have experienced initial clinical benefit (stable disease or better) from most recent checkpoint inhibitor (CPI) therapy
Tumor PD-L1 expression as determined by immunohistochemistry assay of archival tumor tissue or tissue obtained at screening
Histologically confirmed advanced NSCLC
Tumor PD-L1 expression as determined by immunohistochemistry assay of archival tumor tissue or tissue obtained at screening
Histologically confirmed SCLC
Participants may have had prior chemotherapy, radiation therapy, or declined approved therapies for SCLC
Participants whose major lesion was histologically confirmed as squamous cell carcinoma or adenosquamous cell carcinoma of the esophagus
Patients who have previously received not more than 1 prior line of treatment for metastatic disease prior to enrolling to the study
You may not be if
Pregnancy, lactation, or breastfeeding
Known hypersensitivity to any of the components of RO7121661
Active or untreated central nervous system (CNS) metastases
An active second malignancy
Evidence of concomitant diseases, metabolic dysfunction, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications
Known active or uncontrolled bacterial, viral, fungal, mycobacterial, parasitic, or other infection
Treatment with oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1
Active or history of autoimmune disease or immune deficiency
Prior treatment with adoptive cell therapies, such as CAR-T therapies
Concurrent therapy with any other investigational drug \<28 days or 5 half-lives of the drug, whichever is shorter, prior to the first RO7247669 administration
Regular immunosuppressive therapy
Radiotherapy within the last 4 weeks before start of study drug treatment, with the exception of limited palliative radiotherapy
Prior treatment with a T-cell immunoglobulin and mucin domain-3 (TIM-3) inhibitor
Prior therapy for metastatic disease
Adjuvant anti-PD-1 or anti-PD-L1 therapy
\- Prior therapy with any immune CPIs (such as anti-PD-L1/PD-1, CTLA-4)
